Trial Profile

Bispecific NK Engager AFM13 Combined With NK Cells for Patients With Recurrent of Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acimtamig (Primary) ; Cyclophosphamide; Fludarabine; Natural killer cell therapy
Indications Anaplastic large cell lymphoma; B-cell lymphoma; Hodgkin's disease; Mycosis fungoides; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
Focus Adverse reactions; First in man

Most Recent Events

04 Apr 2025 Planned End Date changed from 15 Apr 2025 to 15 Apr 2027.
04 Apr 2025 Planned primary completion date changed from 15 Apr 2025 to 15 Apr 2027.
12 Dec 2023 Results reporting safety and efficacy data at a median follow-up of 14 (6-34) months presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com